SOLICITATION NOTICE
B -- DNA Hypomethylation and Bladder Cancer: A Case Analysis of the Loss of Heterozygosity on Chromosome 9, Aberrant Global DNA Methylation, and Changes in Epigenetic Protein Expression within the New England Bladder Cancer Study
- Notice Date
- 9/10/2010
- Notice Type
- Presolicitation
- NAICS
- 621511
— Medical Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-100200-AV
- Archive Date
- 10/2/2010
- Point of Contact
- Ashley L. Virts,
- E-Mail Address
-
virtsa@mail.nih.gov
(virtsa@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- The National Cancer Institute (NCI), Office of the Director (OD), plans to procure services to analyze the loss of heterozygosity (LOH) on Chromosome 9; DNA hypomethylation and epigenetic protein expression in the etiology of bladder cancer. This acquisition will be processed under FAR Part 12 - Acquisition for Commercial Items and will be made pursuant to the authority in FAR 13.5 to use simplified procedures for commercial acquisitions. The North American Industry Classification System Code is 621511 and the business size standard is $12.5M. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. This is a total small business set-aside. The period of performance for this procurement shall be for twelve months from date of award. The National Cancer Institute previously conducted a case-control study of bladder cancer among men and women in New England. The purpose of the New England Study of Environment and Health (NESEH) is to investigate the number of environmental, occupational, and personal risk factors for bladder cancer. The NCI enrolled patients with bladder cancer who were identified in Maine, New Hampshire, and Vermont, between 2001 and 2004. Multiple biological samples were collected from participants including; blood, buccal cells, and formalin fixed paraffin embedded (FFPE) tumor tissue. The current objective is to study chromosome 9 LOH and global methylation changes in this population. The Government shall ship 500 DNA samples including a computerized list of the 500 subjects that have molecular analysis conducted from the NESEH. The DNA (~100ng) extracted from FFPE tumor tissue will be sent in one batch to the Contractor immediately following the date of award. The samples will be shipped overnight and stored at -20°C. The contractor shall complete the following tasks upon receipt of the samples: For chromosome 9 LOH analysis: a. Five microsatellite markers from each arm of chromosome 9 will be amplified from 100ng genomic DNA for analysis of SNPs using Pyrosequencing technology. Allele loss will be identified by comparison of the tumor sequence to that of an independent non-tumor DNA sample. All samples will be analyzed using a 96 well format. Each plate will be comprised of at least 5% quality control samples randomly dispersed. An allele with ≥ 40% alteration at the identified SNPs compared to the control sequence will be considered a loss. b. All chromatograms and sequencing traces used to determine allele loss levels shall be included as electronic files with all reports. c. If samples fail to sequence, re-amplification at no additional charge to the government shall be completed at least two times if sufficient genomic DNA is available or can be provided by the Government. Milestone and/or phasing charts illustrate a logical sequence of proposed events. These shall be provided to the PO at the beginning of the study. Any remaining, unmodified DNA samples shall be returned to the NCI biorepository or other collaborating institution upon request if not used for the molecular analyses described above. Samples will be shipped on ice to the biorepository within 3 weeks of contract completion. Contractor shall provide results to the NCI Contracting Officer's Technical Representative (COTR) in tabular format to include all chromatograms and sequencing traces. Potential offerors may request a copy of the solicitation from Ashley Virts, Contract Specialist via electronic mail at virtsa@mail.nih.gov or fax (301) 402-4513 by September 17, 2010 11 AM EST. Interested parties shall include the name of company; complete mailing address; point of contacts, phone, fax numbers, and email address; company DUNS number and business size. All questions shall be in writing and addressed to the Contract Specialist noted above. No collect calls will be accepted. In order to receive an award, contractors must be registered and have valid certification in the Central Contractor Registration (CCR) and the Online Representations and Certifications Applications (ORCA). Reference: RFQ-NCI-100200-AV on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-100200-AV/listing.html)
- Record
- SN02276928-W 20100912/100911000302-f922a5bd2cfcc5c5db718a9c5039023a (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |